Published in Law and Health Weekly, August 19th, 2006 "The
development of a vaccine to prevent infection with group A
streptococcus (GAS) is hampered by the widespread diversity of
circulating GAS strains and M protein types, and it is widely
believed that a multivalent vaccine would provide better
protective immunity," according to investigators in Australia.
"We investigated the efficacy of incorporating 3 M protein
serotypic amino-terminal... Want to see the full article?
Welcome to NewsRx! Learn more about a six-week, no-risk free
trial of Law and Health Weekly NewsRx also is available at
LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters,
NewsEdge, and Dow Jones.